Increases in YB-1 protein expression has also been described for other cancers, such as osteosarcoma, prostate cancer, pancreatic adenocarcinoma, colorectal carcinoma, and medulloblastoma, indicating the clinical impact of YB-1 for the progression of these malignant diseases (Kuwano et al, 2003). This evidence concerns the gene YBX1 and colorectal carcinoma.